Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harpoon Therapeutics Inc (NQ: HARP )

23.01 UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 23.01
Bid (Size) 23.00 (6)
Ask (Size) 23.01 (36)
Prev. Close 23.01
Today's Range 23.01 - 23.01
52wk Range 3.110 - 23.21
Shares Outstanding 37,595,787
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
Via Benzinga
Harpoon Therapeutics Inc. (NASDAQ: HARP) Records 52-Week High Thursday Morning
Via Investor Brand Network

Performance

YTD
+109.18%
+109.18%
1 Month
N/A
N/A
3 Month
+2.63%
+2.63%
6 Month
+450.48%
+450.48%
1 Year
+232.42%
+232.42%

More News

Read More
Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth
Via Benzinga
Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings
Via Benzinga
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
Via The Motley Fool
The 3 Best Dividend Growth Stocks to Buy in January 2024
Via InvestorPlace
Peeling Back The Layers: Exploring Harpoon Therapeutics Through Analyst Insights
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
Via Investor's Business Daily
Topics ETFs
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Harpoon Therapeutics Inc. (NASDAQ: HARP) Near the Top of Equities by Percentage Gain on 1/8
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Via Benzinga
Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics
Via Benzinga
US Stocks Mixed; Nasdaq Jumps Over 100 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Merck, the Dow's hottest stock, gets set to report Q4 financials
Via MarketBeat
Topics Stocks
Exposures US Equities
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
Via Investor's Business Daily
Why Is Spirit AeroSystems (SPR) Stock Down 14% Today?
Via InvestorPlace
Why Is LumiraDx (LMDX) Stock Down 13% Today?
Via InvestorPlace
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Via InvestorPlace
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.